Expert Interview
Discussing the potential of CymaBay's seladelpar, a peroxisome proliferator-activated receptor, in development for primary biliary cholangitis
Ticker(s): CBAYInstitution: Southern California Liver Centers
- Hepatologist at Southern California Liver Centers ; formerly Professor of Medicine and Chief of Hepatology at Emory University.
- Manages 25 patients with Primary biliary cirrhosis; specializes in liver diseases, including transplantation, and is an authority on drug-induced liver disease, HCV, NASH, and HBV.
- Has served on an FDA advisory board evaluating new drugs for hepatology and is actively involved in a number of research studies, including the treatment of hepatitis C and B and non-alcoholic steatohepatitis.
Can you please provide a brief introduction of your current practice, incorporating how many patients you treat from PBC?
Added By: sara_adminWhat is the current standard of care and treatment options for your patients with PBC?
Added By: sara_adminWhat are your initial thoughts on seladelpar and the ENHANCE studies' data?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
